The authors found the data inconclusive. They found the evidence for IFNB-1a inadequate owing to methodological limitations of the trial, and state that since trial patients did not self-inject it may not be possible to generalise the results to UK patients. The quantifiable benefits for IFNB-1a were small and, in terms of disability progression, clinically unimportant. The authors conclude that IFNB-1a is an expensive drug with small quantifiable benefits in terms of QALYs.